ECSP17071545A - Inhibidores de bromodominio - Google Patents
Inhibidores de bromodominioInfo
- Publication number
- ECSP17071545A ECSP17071545A ECIEPI201771545A ECPI201771545A ECSP17071545A EC SP17071545 A ECSP17071545 A EC SP17071545A EC IEPI201771545 A ECIEPI201771545 A EC IEPI201771545A EC PI201771545 A ECPI201771545 A EC PI201771545A EC SP17071545 A ECSP17071545 A EC SP17071545A
- Authority
- EC
- Ecuador
- Prior art keywords
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- pharmaceutical compositions
- polymer
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- UWZAJPITKGWMFJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Chemical compound Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O UWZAJPITKGWMFJ-UHFFFAOYSA-N 0.000 abstract 4
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000010922 spray-dried dispersion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17071545A true ECSP17071545A (es) | 2017-12-01 |
Family
ID=57143581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201771545A ECSP17071545A (es) | 2015-04-22 | 2017-10-26 | Inhibidores de bromodominio |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (enExample) |
| EP (1) | EP3285770A4 (enExample) |
| JP (1) | JP2018513863A (enExample) |
| KR (1) | KR20170139119A (enExample) |
| CN (1) | CN107613981A (enExample) |
| AR (1) | AR104340A1 (enExample) |
| AU (1) | AU2016252992A1 (enExample) |
| BR (1) | BR112017022691A2 (enExample) |
| CA (1) | CA2983446C (enExample) |
| CL (1) | CL2017002679A1 (enExample) |
| CO (1) | CO2017011482A2 (enExample) |
| EA (1) | EA201792317A1 (enExample) |
| EC (1) | ECSP17071545A (enExample) |
| HK (1) | HK1243948A1 (enExample) |
| IL (1) | IL255120B (enExample) |
| MX (2) | MX390077B (enExample) |
| PE (1) | PE20180036A1 (enExample) |
| PH (1) | PH12017501933A1 (enExample) |
| SG (1) | SG11201708627TA (enExample) |
| TW (1) | TW201642860A (enExample) |
| WO (1) | WO2016172618A1 (enExample) |
| ZA (1) | ZA201707186B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN110099685A (zh) * | 2016-10-20 | 2019-08-06 | 赛尔基因光迪斯研究公司 | 溴结构域抑制剂 |
| HUE058289T2 (hu) | 2016-10-27 | 2022-07-28 | Celgene Quanticel Res Inc | Brómdomén és extraterminális protein inhibitor kombinációs terápia |
| AU2019309693B2 (en) * | 2018-07-23 | 2023-03-16 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
| EP4294397A1 (en) * | 2021-02-22 | 2023-12-27 | Celgene Quanticel Research, Inc. | Bromodomain (bet) inhibitor for use in treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP3290407B1 (en) * | 2013-10-18 | 2020-01-01 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
| CN110099685A (zh) * | 2016-10-20 | 2019-08-06 | 赛尔基因光迪斯研究公司 | 溴结构域抑制剂 |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL255120B (en) | 2021-03-25 |
| CL2017002679A1 (es) | 2018-05-25 |
| PH12017501933A1 (en) | 2018-03-19 |
| MX390077B (es) | 2025-03-20 |
| KR20170139119A (ko) | 2017-12-18 |
| MX2020010899A (es) | 2022-02-15 |
| WO2016172618A1 (en) | 2016-10-27 |
| JP2018513863A (ja) | 2018-05-31 |
| CA2983446C (en) | 2024-04-09 |
| HK1243948A1 (zh) | 2018-07-27 |
| NZ736630A (en) | 2024-03-22 |
| IL255120A0 (en) | 2017-12-31 |
| CN107613981A (zh) | 2018-01-19 |
| CA2983446A1 (en) | 2016-10-27 |
| CO2017011482A2 (es) | 2018-01-31 |
| EA201792317A1 (ru) | 2018-03-30 |
| MX2017013501A (es) | 2018-02-09 |
| EP3285770A4 (en) | 2018-10-31 |
| TW201642860A (zh) | 2016-12-16 |
| BR112017022691A2 (pt) | 2018-07-17 |
| AU2016252992A1 (en) | 2017-11-09 |
| EP3285770A1 (en) | 2018-02-28 |
| AR104340A1 (es) | 2017-07-12 |
| MX377159B (es) | 2025-03-07 |
| PE20180036A1 (es) | 2018-01-09 |
| SG11201708627TA (en) | 2017-11-29 |
| US20160310423A1 (en) | 2016-10-27 |
| ZA201707186B (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017011482A2 (es) | Inhibidores de bromodominio | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CR20200545A (es) | Inhibidores magl | |
| CL2018001230A1 (es) | Tratamiento de osteoartritis | |
| NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| CL2019001339A1 (es) | Inhibidores de la magl. | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| UY37224A (es) | Derivados aromáticos de sulfonamida | |
| CO2019005038A2 (es) | Inhibidores de magl | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| SV2016005293A (es) | Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2 | |
| BR112018009745A2 (pt) | compostos heterocíclicos para o tratamento de doença | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CU20190002A7 (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1 para el tratamiento del cáncer y composiciones farmacéuticas que los comprenden | |
| CU20150065A7 (es) | Compuestos derivados de bencil 4-((2-(triazol-5-il)acetamido)metil)piperidin-1- carboxilato activos como inhibidores de autotaxina |